Skip to main content
main-content

Medication and diabetic complications

medwireNews top story

Lower gout risk with SGLT2 inhibitors vs GLP-1 receptor agonists

Gout

People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.

medwireNews top story

CVD-REAL 3: Renal benefits of SGLT2 inhibitors confirmed in real-world study

Kidneys

Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.

medwireNews top story

Fasting C-peptide indicates hypoglycemia risk at basal insulin initiation

Blood test

Fasting C-peptide levels can “provide valuable information” to guide the approach to titrating basal insulin in new users with type 2 diabetes, say researchers.

Expert opinion editorial

Cardiorenal syndromes and SGLT2 inhibitor usage

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity [read more].

Get more on: SGLT2 inhibitors | Nephropathy | Cardiovascular disease 

medwireNews top story

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Kidneys

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

medwireNews top story

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Pills in hand

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

Expert opinion editorial

Diabetes and dementia: Addressing the needs of an overlooked population

Diabetes and dementia: Addressing the needs of an overlooked population

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity [read more].

Get more on: Mental health and diabetesDiabetes complications and comorbidities | Diabetes in older adults

medwireNews top story

Recommendations issued for managing SGLT2 inhibitor-associated DKA risk in type 1 diabetes

Checkboxes

Experts have developed consensus recommendations for minimizing diabetic ketoacidosis risk in patients with type 1 diabetes treated with SGLT2 inhibitors.

Patient case study

Cardiovascular risk reduction in type 2 diabetes

Heart and stethoscope

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this case study [read more].

Get more on: Cardiovascular disease | SGLT2 inhibitors | GLP-1 receptor agonists

medwireNews editor's pick

Hepatic glucokinase activation may improve glycemic control in type 2 diabetes

Pills_yellow

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

medwireNews

04-29-2020 | Nephropathy | News

Real-world data back renal benefits with SGLT2 inhibition

Use of sodium-glucose cotransporter 2 inhibitors is associated with a reduced risk for renal events in people with type 2 diabetes in clinical practice, say researchers.

04-23-2020 | GLP-1 agonists | News

Real-world evidence for renoprotective effects of GLP-1 receptor agonists

People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.

04-17-2020 | Insulin glargine | News

Similar glycemic control with glargine U300, U100 for inpatients with type 2 diabetes

Hospitalized people with poorly controlled type 2 diabetes who are treated with insulin glargine U300 have comparable glycemic control to those given the U100 formulation, and may have a lower risk for hypoglycemia, researchers report.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits